Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

ments to continue with Phase 1 clinical study of our proprietary product, TRU-016, as well as other product candidates."

2008 Financial Guidance

Trubion anticipates 2008 revenues to be in the range of $15 million to $20 million earned through the company's Wyeth collaboration. Total operating expenses are expected to be approximately $53 million to $58 million for 2008. The planned increase in 2008 operating expenses is primarily attributable to clinical trial expenses associated with the retreatment study being completed by Trubion for its lead product candidate, TRU-015, manufacturing and clinical costs associated with its TRU-016 product candidate, and increased personnel-related expense. Operating cash requirements in 2008 are expected to be approximately $35 million to $40 million.

Conference Call Details

Trubion will host a conference call and webcast to discuss its fourth-quarter and year-ended 2007 financial results and provide an update on business activities. The call will be held March 13 at 2 p.m. Pacific Time, 5 p.m. Eastern Time. The live event will be available from Trubion's website athttp://investors.trubion.com/events.cfm, or by calling 1 (877) 545-1491 or 1 (719) 325-4931. A replay of the discussion will be available beginning 8 p.m. Eastern Time from Trubion's website or by calling 1 (888) 203-1112 or 1 (719) 457-0820, and entering 7634379. The telephone replay will be available until midnight, Monday, March 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutic
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, the ... global corporations operating in highly regulated industries, announced ... annual Global User Group Conference, Xybion International Exchange, ... Philadelphia, Pennsylvania at the Sheraton Society ... This year,s conference theme ...
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3ORNL study reveals new characteristics of complex oxide surfaces 2ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... ... is a thermally stable, economical and high-performance solution for operations with both high and ... ... heat transfer fluid is a thermally stable, economical and high-performance solution for operations with ...
... in the September 24th issue of Nature , ... technology to explore the ancient history of India, the ... reveals that nearly all Indians carry genomic contributions from ... groups experienced periods of genetic isolation from each other ...
... , ANN ARBOR, Mich., Sept. 23 ... Research Edition version 4.2, a significant product upgrade for ... has been fully committed to supporting academic and non-profit ... features a completely redesigned user-interface, improved search and filter ...
Cached Biology Technology:Paratherm's New GLT Heat Transfer Fluid: Thermally Stable & Lower Minimum Startup Temperatures 2New research reveals the ancestral populations of India and their relationships to modern groups 2New research reveals the ancestral populations of India and their relationships to modern groups 3Compendia Bioscience Announces the Release of Oncomine 4 Research Edition 2
(Date:7/25/2014)... characterized by the existence of numerous isoforms arising ... the protein deeply different characteristics. NRG1 plays an ... development and the different phases occurring after injury ... remyelination and target reinnervation, Researchers at the University ... NRG1 upregulation observed in Schwann cells immediately after ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... sustains irreparable damage in the wake of a heart ... the cardiac muscle contains few stem cells, the tissue ... and cannot contract properly. In their search for ... exploring cardiac "patches" that could be transplanted into the ...
... The chemical is known as an "endocrine disruptor," a substance ... found in everything from plastic drink bottles to the linings ... for cash register receipts not to mention the urine ... BPA has been associated with the development of chronic diseases ...
... animal welfare concern and can cause great economic losses ... whole. A new website has been launched to help ... The website [ http://www.featherwel.org ] has been developed ... Veterinary Sciences to improve bird welfare through FeatherWel, a ...
Cached Biology News:A heart of gold 2BPA + chlorine = bad news 2New website will help farmers ensure hens maintain good feather cover 2
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... sequencing inserts cloned into M13/pUC-based plasmids, plasmids ... polymerase promoters, or lambda gt10 and gt11 ... of 0.1 µg/µl in water. The primers ... using SequiTherm™ EXCEL™ II DNA Polymerase with ...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
Biology Products: